Abstract 241P
Background
Human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV-associated OPSCC) is well known to have a relatively indolent behavior, and it should be staged separately. P16 is a useful surrogate marker for HPV status in OP region. However, the low prevalence of HPV infection in Taiwan (lower than 30%) may cause increased possibility of false positive for p16 staining. This study is aimed to determine the concordance of p16 IHC stain and HPV RNA ISH in Taiwan population.
Methods
There were 141 oropharyngeal cancer patients are retrieved from the archives of VGHTC from 2016 to 2020. HE stain was done and reviewed by 2 pathologist and p16 IHC stain was performed for all cases. Forty-nine (34.8%) of all cases were p16(+) oropharyngeal cancer. HPV-ISH was done for p16(+) oropharyngeal cancer patients.
Results
HPV-ISH found 44 (89.7%) of 49 cases were HPV-ISH (+). On univariate analysis, p16 (+) oropharyngeal cancer patients had better 3-year overall survival (90.4 % vs. 73.4 %, p=0.02) and 3-year disease-free survival (95.4% vs. 65.3%, p=0.0005) than p16(-) oropharyngeal cancer patients. HPV-ISH (+) oropharyngeal cancer patients also had better 3-year overall survival (92.0 % vs. 73.5 %, p=0.02) and 3-year disease-free survival (94.9% vs. 67.4%, p=0.002) than HPV-ISH(-) oropharyngeal cancer patients. We also found p16(+)HPVISH(+) oropharngeal cancer patients had better 3-year disease-free survival than p16(-)HPVISH(-) oropharngeal cancer patients (94.9% vs. 65.3%, p=0.002).
Conclusions
By far, p16 is still a useful surrogate marker for OPSCC in Taiwan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
167P - Genetic testing for prostate cancer: The Indian scenario
Presenter: Ganesh Bakshi
Session: Poster viewing 03
168P - Transcriptional profiling of metastatic hormone sensitive prostate cancer (mHSPC) and distinct features are associated with clinical outcome
Presenter: BYULA JEE
Session: Poster viewing 03
169P - Urine tumor DNA fragmentation profiles provided a novel biomarker for early detection of prostate cancer
Presenter: Nianzeng Xing
Session: Poster viewing 03
170P - Safety, efficacy and pharmacoeconomic implications of low dose abiraterone in prostate cancer
Presenter: Suryakanta Acharya
Session: Poster viewing 03
171P - Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
Presenter: Jin Cho
Session: Poster viewing 03
172P - Impact on management of non-metastatic prostate cancer biochemical recurrence with use of 68Ga PET-PSMA PET/CT scans in single-institution experience
Presenter: Pimchanok Tuitemwong
Session: Poster viewing 03
173P - Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Francis Parnis
Session: Poster viewing 03
175TiP - A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation
Presenter: Junlong Zhuang
Session: Poster viewing 03